Conditional Immortalization of Human Cardiac Fibroblasts for Pro-Fibrotic and Anti-Fibrotic Drug Screening
Frontiers in Bioscience-Landmark · 2026-04-30 · 31 (5)
DOI: 10.31083/fbl49465 ↗At a glance
Journal article in Frontiers in Bioscience-Landmark, published online on 2026-04-30. Written by Sushan Wang and 6 co-authors. Institution: School of Life Sciences, Anhui Medical University, 230601 Hefei, Anhui, China. Major MEDLINE topics: Fibroblasts, Antifibrotic Agents, Myocardium. 35 references. The full text is freely available (open access, CC BY 4.0). Funded by: Shenzhen Science and Technology Innovation Program, Longgang District Science and Technology Innovation Bureau Project, Longgang District Key Specialty Program.
Abstract (original language)
Background
The development of anti-fibrotic therapies for heart failure is hindered by the absence of phenotypically stable and scalable human cardiac fibroblast (CFB) models suitable for pre-clinical drug screening. This study aimed to establish and validate a conditionally immortalized CFB (iCFB) cell line for screening cardiac fibrosis drugs.
Methods
An iCFB line was generated using a doxycycline (dox)-inducible system. The cellular characteristics were evaluated using molecular, protein, and functional analyses. The utility of the model was assessed by exposure to multiple pro-fibrotic stimuli (transforming growth factor-β1 (TGF-β1), angiotensin II, and palmitic acid) and two anti-fibrotic compounds (N-[(1R)-1,2,3,4-tetrahydro-1-naphthalenyl]-1H-benzimidazol-2-amine [NS8593] and pirfenidone). Results: iCFB proliferation was tightly regulated by dox. Upon dox withdrawal, the iCFBs reverted to a quiescent state and exhibited a molecular expression profile (collagen type I alpha 1 chain [COL1A1], periostin [POSTN], gap junction protein alpha 1 [GJA1], and T-box transcription factor 20 [TBX20]) comparable to that of primary CFBs. This phenotypic fidelity, along with a robust capacity for TGF-β1-induced myofibroblast differentiation, was maintained during long-term culture up to population doubling 60. The model responded consistently to diverse pro-fibrotic stimuli, confirming the anti-fibrotic efficacy of the transient receptor potential melastatin 7 (TRPM7) inhibitor, NS8593, and demonstrating the therapeutic potential of the repurposed drug pirfenidone.
Conclusions
We developed a novel iCFB model that integrates long-term expandability, high biological fidelity, and broad responsiveness to fibrotic signaling. This robust platform is well-suited for mechanistic studies and drug screening, thereby facilitating and accelerating the discovery of anti-fibrotic therapeutics.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- School of Life Sciences, Anhui Medical University, 230601 Hefei, Anhui, China.
- Central Laboratory, School of Medicine, The Second Affiliated Hospital, The Chinese University of Hong Kong, Shenzhen & Longgang District People's Hospital of Shenzhen, 518172 Shenzhen, Guangdong, China.
- Department of Cardiology, School of Medicine, The Second Affiliated Hospital, The Chinese University of Hong Kong, Shenzhen & Longgang District People's Hospital of Shenzhen, 518172 Shenzhen, Guangdong, China.
Funding
- Shenzhen Science and Technology Innovation Program
- Longgang District Science and Technology Innovation Bureau Project
- Longgang District Key Specialty Program
Cite
APA
Wang, S., Han, R., Guo, R., Wang, C., Kang, W., Liu, J., & Long, C. (2026). Conditional Immortalization of Human Cardiac Fibroblasts for Pro-Fibrotic and Anti-Fibrotic Drug Screening. Frontiers in Bioscience-Landmark, 31(5). https://doi.org/10.31083/fbl49465
Vancouver
Wang S, Han R, Guo R, Wang C, Kang W, Liu J, et al. Conditional Immortalization of Human Cardiac Fibroblasts for Pro-Fibrotic and Anti-Fibrotic Drug Screening. Frontiers in Bioscience-Landmark. 2026;31(5). doi:10.31083/fbl49465
BibTeX
@article{Wang2026,
author = {Wang, Sushan and Han, Ruijuan and Guo, Rui and Wang, Cheng and Kang, Wenan and Liu, Jia and Long, Canling},
title = {Conditional Immortalization of Human Cardiac Fibroblasts for Pro-Fibrotic and Anti-Fibrotic Drug Screening},
journal = {Frontiers in Bioscience-Landmark},
year = {2026},
volume = {31},
number = {5},
doi = {10.31083/fbl49465}
}
EUVIMED